Intracerebral and subarachnoid haemorrhage
Haemorrhagic stroke from the first hour to secondary prevention, with blood pressure targets, anticoagulant reversal, the INTERACT3 care bundle, surgery, and aneurysmal SAH complications.
Tier 1Condition
Written with AI assistance and fact-checked against the sources below. For exam study, not clinical decisions. How notes are made
At a glance
- Haemorrhage causes about 15 to 20% of strokes but a far larger share of stroke deaths. Clinically it can't be told from infarction, so non-contrast CT decides.
- Intracerebral haemorrhage (ICH): about a third of haematomas expand, mostly in the first 3 to 6 hours. Acute care aims to stop expansion: BP lowering to a systolic of about 140, immediate anticoagulant reversal, and the INTERACT3 bundle.
- Subarachnoid haemorrhage (SAH): about 85% are aneurysmal. Secure the aneurysm early, give nimodipine, and watch for rebleeding, hydrocephalus, delayed cerebral ischaemia and hyponatraemia.
Loading the rest of the note…
Finished reading?
Sources
- Australian and New Zealand Living Clinical Guidelines for Stroke ManagementAU/NZStroke Foundation, Living guideline; 2025 updates added ICH blood pressure and care bundle recommendations (drafted December 2024)
- Notice of public consultation for draft updated stroke guidelines (new ICH blood pressure recommendation and weak recommendation for an ICH care bundle)AU/NZStroke Foundation, December 2024
- 2022 Guideline for the management of patients with spontaneous intracerebral hemorrhageAmerican Heart Association and American Stroke Association (Stroke), 2022
- 2023 Guideline for the management of patients with aneurysmal subarachnoid hemorrhageAmerican Heart Association and American Stroke Association (Stroke), 2023
- The third Intensive Care Bundle with Blood Pressure Reduction in Acute Cerebral Haemorrhage Trial (INTERACT3). Lancet 2023;402:27-40The Lancet, 2023
- Trial of early minimally invasive removal of intracerebral hemorrhage (ENRICH). N Engl J Med 2024;390:1277-89New England Journal of Medicine, 2024
- Andexanet for factor Xa inhibitor-associated acute intracerebral hemorrhage (ANNEXA-I). N Engl J Med 2024;390:1745-55New England Journal of Medicine, 2024
- TGA Medicine Shortage Information: andexanet alfa (Andexxa), discontinued 20 May 2026AU/NZTherapeutic Goods Administration, 2026
- Updated recommendations for warfarin reversal in the setting of four-factor prothrombin complex concentrateAU/NZMedical Journal of Australia (Robinson, McFadyen, Merriman, Tan, Baker and Tran, 2025;222:49-51), 2025
- Last updated
- 14 November 2026
What changed
- 14 November 2026 Turnstile bot check on sign-in and signed-out feedback